Single CRISPR Infusion Cuts LDL Cholesterol 52.5% at One Year in Trial
kimmonismus · x · 2026-09-27
A Cleveland Clinic trial of CTX310, a one-time CRISPR therapy that edits the ANGPTL3 gene in liver cells, showed LDL cholesterol fell 52.5% and triglycerides 47.8% at one year in the four patients receiving the highest dose.
- 15 patients with medication-resistant lipid disorders enrolled
- Reductions persisted for 12 months
- No serious adverse events related to the therapy reported so far, with 15 years of safety follow-up planned
Researchers see it as a potential one-shot, long-lasting treatment for high cholesterol, a major driver of cardiovascular disease.
More from Research
- Google Research open-sources PaperOrchestra, a multi-agent framework for writing AI papers — google-research · 2026-11-16
- Kind ICLR Reviewer Raises Score Despite Unresolved Concerns, Citing the Paper's Value — MarkSchmidtUBC · 2026-11-16
- Hand-editing 0.2% of weights plus 100 CPU-minutes turns an English TTS model into an 18MB Sanskrit one — kastnerkyle · 2026-11-16
- Why chirality matters for AI for Science: enantiomers behave differently in biology — madeofAjala · 2026-11-16
- RSS 2027 submissions open with FAQ clarifying two-stage review and negative-result bar — GeorgiaChal · 2026-11-16
- Mobile AI Factory: agents auto-build on-device SLMs with 19x less GPU time — pmttyji · 2026-11-16